{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:43:18Z","timestamp":1768560198071,"version":"3.49.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,15]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Recent analyses have suggested a possible negative impact of prior autologous stem cell transplantation on outcomes with idecabtagene vicleucel (ide-cel) chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. Our registry-based analysis of &amp;gt;800 ide-cel recipients did not identify any such association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031426","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T18:17:11Z","timestamp":1764008231000},"page":"312-315","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-5043","authenticated-orcid":false,"given":"Christy","family":"Khouderchah","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"3Department of Pharmacy, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Othman S.","family":"Akhtar","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-4770","authenticated-orcid":false,"given":"Emily C.","family":"Liang","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-5988","authenticated-orcid":false,"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"8","key":"2026011511215104900_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026011511215104900_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 Cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation [abstract]","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011511215104900_bib3","first-page":"232","article-title":"Idecabtagene vicleucel (ide-cel) in patients (pts) with clinical high-risk early relapse multiple myeloma (MM) without front-line (1L) autologous stem cell transplantation (ASCT): KarMMa-2 Cohort 2B [abstract]","volume":"8","author":"Leleu","year":"2024","journal-title":"Hemasphere"},{"issue":"11","key":"2026011511215104900_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2026011511215104900_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.2024026216","article-title":"Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma","volume":"146","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026011511215104900_bib6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjh.19505","article-title":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): a real-world IFM study from the DESCAR-T registry","volume":"205","author":"Ferment","year":"2024","journal-title":"Br J Haematol"},{"issue":"14","key":"2026011511215104900_bib7","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2025028330","article-title":"Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST","volume":"146","author":"Merz","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026011511215104900_bib8","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026011511215104900_bib9","doi-asserted-by":"crossref","first-page":"1240966","DOI":"10.3389\/fonc.2023.1240966","article-title":"Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling","volume":"13","author":"Banerjee","year":"2023","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"2026011511215104900_bib10","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2024-198740","article-title":"Cross-cohort correlative analysis of clinically high-risk patients (pts) treated with idecabtagene vicleucel (ide-cel) in KarMMa-2: association between progression-free survival (PFS) and tumor burden and immune status at apheresis [abstract]","volume":"144","author":"Basudhar","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011511215104900_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134369","article-title":"Effects of prior alkylating therapies on preinfusion patient characteristics and starting material for CAR T cell product manufacturing in late-line multiple myeloma [abstract]","volume":"136","author":"Rytlewski","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2026011511215104900_bib12","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2026011511215104900_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2024-212135","article-title":"Previous HDM\/ASCT adversely impacts PFS with BCMA-directed CAR T-cell therapy in multiple myeloma [abstract]","volume":"144","author":"Gustine","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011511215104900_bib14","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2024-200829","article-title":"Idecabtagene vicleucel (ide-cel) in patients (pts) with newly diagnosed multiple myeloma (NDMM) with an inadequate response to front-line autologous stem cell transplantation (ASCT): KarMMa-2 Cohort 2c extended follow-up [abstract]","volume":"144","author":"Paul","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026011511215104900_bib15","first-page":"LBA1","article-title":"Phase II multicenter trial of idecabtagene vicleucel (ide-cel) followed by lenalidomide maintenance for multiple myeloma patients with sub-optimal response after an upfront autologous hematopoietic cell transplantation: top line results from the BMT CTN 1902 clinical trial","volume":"31","author":"Garfall","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"suppl 1","key":"2026011511215104900_bib16","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1182\/blood-2024-212230","article-title":"Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation [abstract]","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026011511215104900_bib17","first-page":"350","article-title":"Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"2026011511215104900_bib18","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/bloodadvances.2024014970","article-title":"Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study","volume":"9","author":"Akhtar","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/3\/312\/2498137\/blood_bld-2025-031426-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/3\/312\/2498137\/blood_bld-2025-031426-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:22:00Z","timestamp":1768494120000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/3\/312\/548419\/Prior-transplantation-and-idecabtagene-vicleucel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031426","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2026,1,15]]}}}